Bringing the fundamentals into focus…
Back to Abbott Laboratories
How Abbott Laboratories stacks up
ABT · against 24 other Healthcare companies of similar size
Valuation
57/ 100
Below the middle of the pack.
Ranked #18 of 25 · scores higher than 29% of peers
Bars: peers in each 10-point band of the valuation score7 peers with a valuation score of 50–59, including ABT · Click a bar to see the companies
Why valuation scores 57?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 5.0% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 2.9% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 73% of peers. Free cash flow yield: 4.1% vs peer median 0.0%
Metric by metric
Position: dot = ABT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ABT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 25 reported | 2.8% | 3.8% | 25% | 30% | |
| EBITDA yieldHigher is better · 25 reported | 5.4% | 6.8% | 21% | 50% | |
| Free cash flow yieldHigher is better · 24 reported | 3.9% | 4.9% | 26% | 20% | |
| Book yieldHigher is better · 23 reported | 27.0% | 18.1% | 73% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ABT| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 177.5B USD | 92 | 71 | |
| 2 | 108.6B USD | 88 | 66 | |
| 3 | 97.5B USD | 87 | 67 | |
| 4 | 126.1B USD | 83 | 62 | |
| 4 | 540.4B BRL (≈$97.3B) | 83 | 64 | |
| 14 | 116.5B USD | 63 | 57 | |
| 15 | 100.2B USD | 61 | 68 | |
| 16 | 249.4B USD | 60 | 55 | |
| 17 | 119.1B USD | 59 | 57 | |
| 18 | 189.3B USD | 57 | 45 | |
| 19 | 134.5B USD | 55 | 70 | |
| 20 | 356.9B USD | 54 | 37 | |
| 21 | 161.8B USD | 53 | 50 | |
| 21 | 258.2B USD | 53 | 47 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score